Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNP-Cat-B
- Development stage
- Preclinical
- Lead developer
- Stanford University
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
TNP-Cat-B is a tumor-enzyme activatable theranostic nanoprobe developed for the treatment and imaging of glioblastoma (GBM). It comprises ferumoxytol nanoparticles conjugated to the cytotoxic tubulin inhibitor monomethyl auristatin E (MMAE) via a linker that is specifically cleaved by the enzyme cathepsin B, which is overexpressed in glioblastoma cells. This design allows for targeted drug release within the tumor microenvironment, minimizing systemic toxicity. Additionally, the ferumoxytol component acts as a contrast agent for magnetic resonance imaging (MRI), allowing for the non-invasive monitoring of drug delivery and therapeutic efficacy through T2* relaxation time measurements. In preclinical studies, TNP-Cat-B has been evaluated as a monotherapy and in combination with TNP-MMP-14, a vascular-disrupting nanoprobe intended to open the blood-brain barrier to maximize delivery.
- Other names
- ferumoxytol-MMAE cathepsin-B-activatable nanoprobe
02
Targets
CTSB (Cathepsin B)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on TNP-Cat-B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNP-Cat-B.